Austex Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 3.00 Cr
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
- Revenue Growth 35.76%
- Profit Growth 1.07%
- Ebitda 3.71%
- Net Worth -61.03%
- Total Assets 18.81%
About Austex Pharmaceutical
Austex Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 September 2016 (Eight years and four months 29 days old ). Its registered office is in Howrah, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹2.00 Cr.
Sumit Singh and Shalini Singh serve as directors at the Company.
Company Details
- Location
Howrah, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51909WB2016PTC217765
- Company No.
217765
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Sep 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Austex Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Singh  | Director | 27-Sep-2021 | Current |
| Shalini Singh | Director | 07-Aug-2024 | Current |
Financial Performance of Austex Pharmaceutical.
Austex Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.76% increase. The company also saw a slight improvement in profitability, with a 1.07% increase in profit. The company's net worth observed a substantial decline by a decrease of 61.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Austex Pharmaceutical?
In 2023, Austex Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ausilabs Private LimitedSumit Singh is a mutual person
- Ausicare India Private Limited
Sumit Singh is a mutual person
Charges (Loans)
₹2.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Aug 2024 | Indian Overseas Bank | ₹2.00 Cr | Open |
How Many Employees Work at Austex Pharmaceutical?
Unlock and access historical data on people associated with Austex Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Austex Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Austex Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
